Predictive Value of the KELIM Index for Progression-Free Survival in Ovarian Cancer Under Current Treatment Modalities.

Int J Womens Health · 2025 · PMC12301136 · PMID 40726508

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although PARPi (HR=1.53, P=0.213) and bevacizumab (HR=1.64, P=0.57) demonstrated a trend towards a benefit in PFS, which aligns with the findings from related ovarian cancer studies and is mechanistically plausible, these differences did not reach statistical significance due to the small number of patients in subgroups (n<10) and the crossover use of PARPi and bevacizumab in some patients.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.